Mutations within the same gene can cause different phenotypes. Mutation-specific phenotypes, where a single mutation is associated with a different phenotype, are rare. Activating or inactivating mutations in a single gene can cause opposite phenotypes, as seen in the genes encoding the pancreatic β cell potassium channel subunits where activating mutations cause neonatal diabetes but inactivating mutations cause congenital hyperinsulinism.[@R1] The location of a mutation within a gene can cause different phenotypes, as seen in *NOTCH2* where mutations affecting the epidermal growth factor (EGF) repeats and ankyrin repeats (ANK) domain of *NOTCH2* cause Alagille syndrome[@R2] \[MIM 118450\], but those in the terminal exon 34 result in Hajdu--Cheney syndrome[@R3] [@R4] \[MIM 102500\]. The same mutation can cause a different phenotype according to the patient\'s age. In *HNF4A*, there are not mutation-specific phenotypes, but as a result of increased insulin secretion seen in early life, birth weight is increased by 790 g and there is neonatal hypoglycaemia.[@R5] Later in life, diabetes develops (median age 24 years at diagnosis[@R6]) due to decreased insulin secretion. No renal phenotype associated with *HNF4A* mutations has been described, although the knockout mouse of the related transcription factor HNF1A was described as having Fanconi syndrome.[@R7]

Fanconi syndrome \[MIM 134600\] is a generalised dysfunction of the renal proximal tubule in which the genetic aetiology has been described in a variety of syndromes that include Cystinosis \[MIM 219800\], Lowe syndrome \[MIM 309000\] or Fanconi-Bickel syndrome \[MIM 227810\]. As a consequence of proximal tubulopathy, there is failure of resorption of glucose, amino acids, phosphate, low molecular weight proteins, bicarbonate and urate. The usual presenting clinical features are growth failure and rickets in childhood.[@R8] Treatment is based on replacing the lost solutes. Families with autosomal-dominant idiopathic Fanconi syndrome have been reported.[@R9][@R15] Despite a study showing linkage to chromosome 15 in a single family,[@R16] no genetic cause has been established.

We studied a family with three individuals affected with a similar clinical phenotype of Fanconi syndrome and nephrocalcinosis in addition to neonatal hypoglycaemia and macrosomia ([figure 1](#JMEDGENET2013102066F1){ref-type="fig"}). Two sisters were diagnosed with Fanconi syndrome due to short stature and rickets. Genetic testing for mutations in the *PHEX*, *FGF23*, *DMP1*, *ENPP1* and *SLC34A3* genes did not confirm a genetic diagnosis of hypophosphataemic rickets. Urine and serum analysis in these three affected family members demonstrated a full Fanconi syndrome with heavy low molecular weight proteinuria, aminoaciduria, glycosuria and a low serum urate (see online supplementary tables S1 and S2). Additionally, they had nephrocalcinosis diagnosed by renal ultrasound ([figure 2](#JMEDGENET2013102066F2){ref-type="fig"}B) with atypical biochemical features. One sister gave birth to a macrosomic baby (birth weight \>99th centile for gestation) with neonatal hyperinsulinism requiring diazoxide treatment, which was also seen in the sisters ([figure 1](#JMEDGENET2013102066F1){ref-type="fig"}). These latter features were consistent with an *HNF4A* mutation, but no *HNF4A* renal phenotype has previously been described. After informed consent was provided, sequence analysis of the *HNF4A* gene identified a heterozygous p.R76W mutation (c.226C\>T according to the Chartier *et al*[@R17] cDNA reference sequence, using methods previously described by Flanagan *et al*[@R18]) in the proband, mother and maternal aunt. The mutation had arisen in the proband\'s maternal grandfather who is a germline and somatic mosaic (26% mutation in leukocyte DNA). This suggested that a novel renal and β cell phenotype cosegregated with the R76W mutation within one family.

![Partial pedigrees. Pedigrees of the four families demonstrate co-segregation of the p.R76W *HNF4A* mutation with neonatal hypoglycaemia and Fanconi syndrome. The genotype is given below each symbol where known. For each proband, age at follow-up, mutation, birth weight Z score, hypoglycaemia treatment and duration, age of diabetes diagnosis/diabetes management, age of diagnosis of Fanconi syndrome, glomerular filtration rate (GFR) (mLs/min/1.73 m^2^) and height Z score are provided. The mutation is reported according to the *HNF4A* cDNA sequence published by Chartier *et al*[@R17] but has also been described as p.R85W according to reference sequence NM_000457.3 or p.R63W using NM_175914.3 (LRG_483).[@R22] Birth weight and height Z scores are calculated from UK 1990 child growth including standard children and preterm infants. Our proband\'s grandfather developed diabetes at 51 years of age with a body mass index (BMI) of 30.5. He is managed with weight loss alone with a recent HbA1c of 39 mmol/mol. The mutation was present in his leukocyte DNA at 26% but it is not known if the mutation load in his pancreas is sufficient to cause his diabetes. He had no reported neonatal hypoglycaemia or Fanconi syndrome (data not shown). Neither the proband, his mother, nor her sister are currently diabetic, but they undergo surveillance using an annual oral glucose tolerance test.](jmedgenet-2013-102066f01){#JMEDGENET2013102066F1}
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\(A\) Boxplots comparing (1) urinary retinol-binding protein, (2) mean urinary amino acid Z scores, (3) urinary glucose, (4) serum urate, (5 and 6) urinary and serum calcium, (7) urinary phosphate and (8) urinary oxalate between R76W mutations and other *HNF4A* mutations. Boxplots demonstrate the phenotype is mutation specific by comparing patients with the mutation to patients with other *HNF4A* mutations. We compared analysis of fasted first-void urine and renal ultrasound scans between patients with the R76W mutation and 20 patients with other mutations in *HNF4A.* Medians were compared using the Mann--Whitney U Test or Fisher\'s exact test, and a mean urinary amino acid Z score calculated (with control data being derived from laboratory reference ranges). Other *HNF4A* mutations comprise: S34X, R80Q, A120D, R125W (2), R125Q, V190A, D206Y, R244W, L260P, L263P, E276Q, R303H, R303C, I314F, L332P, delEx1-7, c.466-2A\>G, c.1delA, t(3;20)(p21.2;q12). (Laboratory reference ranges are shown with dashed lines (where a single line is present the reference range is below this value).). (B) Renal ultrasonographic images comparing nephrocalcinosis changes to normal kidney. Nephrocalcinosis is demonstrated by increased reflectivity of the renal pyramids, as seen in the top panel (patient heterozygous for R76W), compared to normal ultrasound images in the bottom panel (patient with balanced translocation t(3;20)(p21.2;q12) described by Gloyn *et al*[@R23]).
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We sought to examine if other patients with the R76W mutation also had a renal phenotype. We identified three additional patients with the R76W mutation from a cohort of 147 probands with *HNF4A* mutations ([figure 1](#JMEDGENET2013102066F1){ref-type="fig"}). All patients had hyperinsulinism and/or macrosomia, and two subsequently developed diabetes. One has been previously published.[@R18] We investigated these patients for the renal phenotype seen in our first family using the methods described above (see online supplementary tables S1 and S2). The additional three patients with the heterozygous p.R76W *HNF4A* mutation also had a phenotype of Fanconi syndrome and nephrocalcinosis in addition to the pancreatic β cell phenotype. This suggested that the Fanconi syndrome was a consistent feature of the *HNF4A* R76W mutation.

We went on to establish if patients with other *HNF4A* mutations also had Fanconi syndrome. We took urine and serum samples from 20 diabetic patients with *HNF4A* mutations other than R76W and investigated biochemical and radiological features ([figure 2](#JMEDGENET2013102066F2){ref-type="fig"}A, see online supplementary tables S1 and S2). Our results demonstrate there was a specific phenotype seen in the six patients with the R76W mutation. This includes the classical features of Fanconi syndrome with a urinary leak of low molecular weight proteins, amino acids (mean Z score of urinary amino acids for R76W heterozygotes was 22.9, compared to 0.2 for other mutations (individual amino acid data is shown in online supplementary table S2)), urate, glucose and phosphate. Additionally, there were features not typically seen, of hypercalciuria, hyperoxaluria and hypermagnesaemia. Nephrocalcinosis was present in all patients with the R76W mutation, but no patients with other mutations in the *HNF4A* gene. The R76W mutation carriers have renal impairment with a median creatinine of 114 μmol/L. These results demonstrate a previously undescribed renal phenotype for the R76W mutation and show that patients with other mutations in *HNF4A* do not exhibit these specific renal features.

There is a single reported patient outside of our series that has the R76W mutation.[@R19] This patient had features of Fanconi syndrome in addition to neonatal hyperinsulinism. Additional features included hepatomegaly with elevated transaminases at 3 months of age and abundant glycogen on liver biopsy. Renal ultrasound findings were not reported, so nephrocalcinosis cannot be excluded. No patients in our series had hepatosplenomegaly.

The specific phenotype seen with the R76W *HNF4A* mutation suggests this mutated hepatic transcription factor binds to different target(s). The R76 residue is in the DNA-binding domain and directly contacts the DNA DR1 response element comprised of AGGTCA half sites.[@R20] In functional studies, there was a decrease in DNA binding, but this was not mutation specific.[@R20] Our modelling demonstrates differences in charge and hydrophobicity with the R76W mutation compared to wild type in areas of intimate DNA contact (see online supplementary figure S3). Therefore, the mechanism of the mutation-specific phenotype is likely to involve altered DNA binding, but the details of this and the novel target bound/unbound are not known.

The tubulopathy we see in these patients is a generalised Fanconi syndrome with extended features, which include nephrocalcinosis and alterations in the handling of magnesium, oxalate and calcium, with a subsequent effect on calcium homeostasis. We did not see a significant acidosis which is usually described in Fanconi syndrome. We hypothesise that high urine concentrations of calcium, phosphate and oxalate predispose to renal tract calcification. The renal impairment may reflect damage from calcification, or altered tubular excretion of creatinine. Glycosuria may have a delaying effect on the development of diabetes in these individuals, akin to treatment with SGLT2 inhibitors. The changes we have seen in magnesium handling with both elevated serum and urine levels are intriguing; this appears to be an overflow rather than a leak as seen with calcium, phosphate and urate. Proximal tubular transport is via a variety of mechanisms[@R8]: cotransport of glucose, amino acids and phosphate with sodium generates energy for non-sodium ion transport against an electrochemical gradient. Low molecular weight proteins are reabsorbed using the endosomal pathway, and urate handling is through apical URAT1 and luminal GLUT9 and a complex series of organic anion and cation transporters. Calcium resorption is mediated by the paracellular route via the increased potential difference set up by the sodium cotransporters, and 60% of calcium resorption occurs in the proximal tubule. The mechanisms for the generalised dysfunction in Fanconi syndrome remain unsolved, but hypotheses include disturbances in cellular energy metabolism, membrane characteristics and transporters.[@R21] Present understanding of physiology is inadequate to fully explain the extent of the tubulopathy.

In conclusion, we present a novel atypical cause of autosomal-dominant Fanconi syndrome with nephrocalcinosis caused by the *HNF4A* R76W mutation. This unique mutation-specific phenotype is characterised by increased birth weight, neonatal hyperinsulinaemic hypoglycaemia which may progress to diabetes, and Fanconi syndrome with nephrocalcinosis. It has not been described in patients with other mutations in *HNF4A*, or other monogenic diabetes genes. This finding provides new insights into the genetic regulation of proximal tubular maturation, as well as the precise renal effects *HNF4A* gene mutations. In silico modelling suggests a pivotal role for this particular residue in DNA binding, and we hypothesise that the renal phenotype is a consequence of a defective interaction of HNF4A with major regulatory genes. The fact that there are no other mutations in *HNF4A* that cause this phenotype suggests that this particular residue must be crucial in the renal proximal tubule. In summary, this is an unusual case of a mutation-specific phenotype in *HNF4A* with a renal Fanconi syndrome and nephrocalcinosis in addition to the previously described β cell phenotype.
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